Hybrid eventIn-person & virtual
March 18–20, 2027Singapore · Village Hotel Changi

Talk Details · Materials 2027

Preparation of nanoparticles loaded by dimethyl fumarate and their physical and chemical properties study

Oral · In-Person · Day 1

Abstract

About this talk

Multiple Sclerosis (MS) is a progressive illness of the central nervous system characterized by the deterioration of the myelin sheath around nerve cells, causing motor, sensory, or cognitive dysfunctions that impact mobility and safety. MS progression can occur through relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA). DMF is the active pharmaceutical ingredient used in this study. It is an oral treatment for multiple sclerosis (MS) known for its antioxidative and immunomodulatory properties. In the context of this research, DMF is encapsulated within solid lipid nanoparticles (SLNs) to improve its delivery and efficacy in treating MS. This study aimed to use platelet membranes and polymeric nanoparticles (PNs) to develop a drug delivery system that mimics biological cells to treat MS. Here, we produced and characterized solid lipid nanoparticles (SLNs) containing dimethyl fumarate (DMF). To make SLNs, DMF is combined with biocompatible lipids using hot emulsion and ultrasonication techniques. These DMF-SLNs were characterized using transmission electron microscopy (TEM), scanning electron microscopy (SEM), FTIR spectroscopy, and a zeta meter instrument. Characterization revealed that the optimal SLNs had a polydispersity index of (0.28, 0.96, 0.77), a zeta potential of (-22.73 mV, -28.7 mV, and -30.13 mV), and a mean particle size of (562 nm, 1997 nm, and 849 nm). The application of nanotechnology in the medical area enhances the detection and treatment of a wide range of disorders. Consequently, increasing their efficacy because of the ability of NPs to provide a potential option for diagnosing and treating brain diseases and disorder conditions, which have proven challenging for many years. The results of this study suggest that the present formulation may be a potential longer-acting formulation for the improved management of MS. SLNs could significantly change the treatment of many illnesses by providing effective drug delivery.

Speaker

About the speaker

Abdulazeez Basim A Hussein

Abdulazeez Basim A Hussein

University Putra Malaysia, Malaysia

View full speaker profile →

Join the Materials 2027 delegation

Singapore · March 18–20, 2027· Hybrid · in-person & virtual

Register as Delegate →

Attend without presenting.